Testing new drug combos for multiple myeloma with a specific gene change
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests if adding venetoclax to standard myeloma treatments can help patients with a specific gene change called t(11;14). There are different treatment combinations for people newly diagnosed or who have already tried other therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have active multiple myeloma with a specific genetic marker (t(11;14)).
- If you've had prior treatment, it must not have included venetoclax.
- If you're newly diagnosed, you can only have had up to one cycle of standard treatment and you should not be planning a stem cell transplant.
- You need adequate kidney function (creatinine clearance at least 30 mL/min), blood cell counts, and liver function.
- You must have measurable disease, which can be checked through blood or urine tests.
- You must agree to strict birth control measures if applicable, and follow the Revlimid safety program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This Phase 1/2 trial tests whether combining belantamab mafodotin with venetoclax can treat multiple myeloma that has come back or did not respond (relapsed/refractory). It focuses on a specific myeloma subtype with a t(11;14) genetic marker, aiming to reduce the cancer in people who have already had several treatments.
This trial tests a new treatment for people with newly diagnosed multiple myeloma that has not been treated before. It looks at whether adding a targeted therapy to standard treatment helps control the disease better.
This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This early-phase study tests how safe a new drug (CC-92480) is and how much it stays in the body, when given with other standard or study treatments. It’s for people whose multiple myeloma has come back or did not respond after prior therapy, with the goal of improving disease control.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.